+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours

Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours

Nuclear Medicine Communications 27(4): 371-376

Bombesin is a peptide that was initially isolated from frog skin and which belongs to a large group of neuropeptides with many biological functions. The human equivalent is gastrin-releasing peptide (GRP), whose receptors are over-expressed in a variety of malignant tumours. To prepare a HYNIC-[Lys 3]-bombesin analogue that could be easily labelled with 99mTc from lyophilized kit formulations and to evaluate its potential as an imaging agent for GRP receptor-positive tumours. HYNIC was conjugated to the epsilon-amino group of Lys 3 residue at the N-terminal region of bombesin via succinimidyl-N-Boc-HYNIC at pH 9.0. 99mTc labelling was performed by addition of sodium pertechnetate solution and 0.2 M phosphate buffer pH 7.0 to a lyophilized formulation. Stability studies were carried out by reversed phase HPLC and ITLC-SG analyses in serum and cysteine solutions. In-vitro internalization was tested using human prostate cancer PC-3 cells with blocked and non-blocked receptors. Biodistribution and tumour uptake were determined in PC-3 tumour-bearing nude mice. 99mTc-EDDA/HYNIC-[Lys 3]-bombesin was obtained with radiochemical purities >93% and high specific activity ( approximately 0.1 GBq.nmol). Results of in-vitro studies demonstrated a high stability in serum and cysteine solutions, specific cell receptor binding and rapid internalization. Biodistribution data showed a rapid blood clearance, with predominantly renal excretion and specific binding towards GRP receptor-positive tissues such as pancreas and PC-3 tumours. 99mTc-EDDA/HYNIC-[Lys 3]-bombesin obtained from lyophilized kit formulations has promising characteristics for the diagnosis of malignant tumours that over-express the GRP receptor.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 049988595

Download citation: RISBibTeXText

PMID: 16531924

DOI: 10.1097/01.mnm.0000202863.52046.7f

Related references

Targeted imaging of gastrin-releasing peptide receptors with 99mTc-EDDA/HYNIC-[Lys3]-bombesin: biokinetics and dosimetry in women. Nuclear Medicine Communications 29(8): 741-747, 2008

In vitro evaluation of (99m)Tc-EDDA/tricine-HYNIC-Q-Litorin in gastrin-releasing peptide receptor positive tumor cell lines. Journal of Drug Targeting 21(4): 383-388, 2013

In vitro and in vivo evaluation of a 99mTc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors. Nuclear Medicine and Biology 29(5): 553-560, 2002

99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. European Journal of Nuclear Medicine 27(9): 1318-1325, 2000

A freeze-dried kit formulation for the preparation of Lys(27)(99mTc-EDDA/HYNIC)-Exendin(9-39)/99mTc-EDDA/HYNIC-Tyr3-Octreotide to detect benign and malignant insulinomas. Nuclear Medicine and Biology 42(12): 911-916, 2015

Preparation via coligand exchange and characterization of (99mTc-EDDA-HYNIC-D-Phe1,Tyr3)Octreotide (99mTc-EDDA/HYNIC-TOC). Journal of Labelled Compounds and Radiopharmaceuticals 46(4): 307-318, 2003

Evaluation of three different families of bombesin receptor radioantagonists for targeted imaging and therapy of gastrin releasing peptide receptor (GRP-R) positive tumors. Journal of Medicinal Chemistry 58(2): 682-691, 2015

Preparation and biological evaluation of [(99m)Tc/EDDA/Tricine/HYNIC(0), BzThi(3)]-octreotide for somatostatin receptor-positive tumor imaging. Cancer BioTherapy and Radiopharmaceuticals 28(3): 240-247, 2013

New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors. Quarterly Journal of Nuclear Medicine and Molecular Imaging 51(1): 42-50, 2007

Evaluation of a 64Cu-labeled bombesin analogue for diagnosis of gastrin-releasing peptide receptor positive tumors by microPET imaging. Journal of Labelled Compounds & Radiopharmaceuticals 44(Suppl. 1): S81-S83, 2001

Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. European Journal of Nuclear Medicine and Molecular Imaging 40(4): 524-531, 2013

Synthesis, development and preclinical comparison of two new peptide based freeze-dried kit formulation Tc-99m-EDDA-Tricine-HYNIC-TOC and Tc-99m-EDDA-Tricine-HYNIC-TATE for somatostatin receptor positive tumor scintigraphy. Daru 14(4): 183-189, 2006

Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors. Bioconjugate Chemistry 19(12): 2432-2439, 2008

Lys3-bombesin conjugated to 99mTc-labelled gold nanoparticles for in vivo gastrin releasing peptide-receptor imaging. Journal of Biomedical Nanotechnology 6(4): 375-384, 2010

Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma. Cancer BioTherapy and Radiopharmaceuticals 22(5): 613-628, 2007